S
Sanna-Kaisa Herukka
Researcher at University of Eastern Finland
Publications - 152
Citations - 7915
Sanna-Kaisa Herukka is an academic researcher from University of Eastern Finland. The author has contributed to research in topics: Dementia & Cerebrospinal fluid. The author has an hindex of 38, co-authored 132 publications receiving 6681 citations. Previous affiliations of Sanna-Kaisa Herukka include Hospital de Sant Pau & Oulu University Hospital.
Papers
More filters
Journal ArticleDOI
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Niklas Mattsson,Henrik Zetterberg,Oskar Hansson,Niels Andreasen,Lucilla Parnetti,Michael Jonsson,Sanna-Kaisa Herukka,Wiesje M. van der Flier,Marinus A. Blankenstein,Michael Ewers,Kenneth Rich,Elmar Kaiser,Marcel M. Verbeek,Magda Tsolaki,Ezra Mulugeta,Erik Rosén,Dag Aarsland,Pieter Jelle Visser,Johannes Schröder,Jan Marcusson,Mony J. de Leon,Harald Hampel,Philip Scheltens,Tuula Pirttilä,Anders Wallin,Maria Eriksdotter Jönhagen,Lennart Minthon,Bengt Winblad,Kaj Blennow +28 more
TL;DR: This multicenter study found that CSF Abeta42, T-t Tau, and P-tau identify incipient AD with good accuracy, but less accurately than reported from single-center studies.
Journal ArticleDOI
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Tero Tapiola,Irina Alafuzoff,Sanna-Kaisa Herukka,Laura Parkkinen,Päivi Hartikainen,Hilkka Soininen,Tuula Pirttilä +6 more
TL;DR: Cerebrospinal fluid Abeta42 and tau proteins are biomarkers of AD-associated pathologic changes in the brain and the combination of abnormally low CSF Abeta 42 level and abnormally high CSF tau level predicted the presence of AD pathologic features with high accuracy.
Journal ArticleDOI
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Niklas Mattsson,Ulf Andreasson,Staffan Persson,Hiroyuki Arai,Sat Dev Batish,Sergio Bernardini,Luisella Bocchio-Chiavetto,Marinus A. Blankenstein,Maria Berrocal Carrillo,Sonia Chalbot,Els Coart,Davide Chiasserini,Neal Cutler,Gunilla Dahlfors,Stefan Duller,Anne M. Fagan,Orestes Vicente Forlenza,Giovanni B. Frisoni,Douglas Galasko,Daniela Galimberti,Harald Hampel,Aase Handberg,Michael T. Heneka,Adrianna Z. Herskovits,Sanna-Kaisa Herukka,David M. Holtzman,Christian Humpel,Bradley T. Hyman,Khalid Iqbal,Mathias Jucker,Stephan A. Kaeser,Elmar Kaiser,Elisabeth Kapaki,Daniel Kidd,Péter Klivényi,Cindy Soendersoe Knudsen,Markus P. Kummer,James Lui,Albert Lladó,Piotr Lewczuk,Qiao-Xin Li,Ralph N. Martins,Colin L. Masters,John McAuliffe,Marc Mercken,Abhay Moghekar,José Luis Molinuevo,Thomas J. Montine,William Nowatzke,Richard O'Brien,Markus Otto,George P. Paraskevas,Lucilla Parnetti,Ronald C. Petersen,David Prvulovic,Herman P M de Reus,Robert A. Rissman,Elio Scarpini,Alessandro Stefani,Hilkka Soininen,Johannes Schröder,Leslie M. Shaw,Anders Skinningsrud,Brith Skrogstad,Annette Spreer,Leda Leme Talib,Charlotte E. Teunissen,John Q. Trojanowski,Hayrettin Tumani,Robert M. Umek,Bianca Van Broeck,Hugo Vanderstichele,László Vécsei,Marcel M. Verbeek,Manfred Windisch,Jing Zhang,Henrik Zetterberg,Kaj Blennow +77 more
TL;DR: The cerebrospinal fluid biomarkers amyloid β (Aβ)‐42, total‐Tau (T‐tau), and phosphorylated‐t Tau (P‐tAU) demonstrate good diagnostic accuracy for Alzheimer's disease (AD), but there are large variations in biomarker measurements between studies, and between and within laboratories.
Journal ArticleDOI
CSF biomarker variability in the Alzheimer's Association quality control program
Niklas Mattsson,Niklas Mattsson,Ulf Andreasson,Staffan Persson,Maria C. Carrillo,Steven J. Collins,Sonia Chalbot,Neal Cutler,Diane Dufour-Rainfray,Anne M. Fagan,Niels H. H. Heegaard,Ging-Yuek Robin Hsiung,Bradley T. Hyman,Khalid Iqbal,D. Richard Lachno,Alberto Lleó,Piotr Lewczuk,José Luis Molinuevo,Piero Parchi,Axel Regeniter,Robert A. Rissman,Hanna Rosenmann,Giuseppe Sancesario,Johannes Schröder,Leslie M. Shaw,Charlotte E. Teunissen,John Q. Trojanowski,Hugo Vanderstichele,Manu Vandijck,Marcel M. Verbeek,Henrik Zetterberg,Henrik Zetterberg,Kaj Blennow,Stephan A. Käser,Aladro José A. Rojo,Marilyn S. Albert,Daniel Alcolea,Anna Antonell,Hiroyuki Arai,Silvana Archetti,Eva Arkblad,Inês Baldeiras,Ales Bartos,Dev Batish,Aurélie Bedel,Daniele Bentue-Ferrer,Flora Berisha,Sergio Bernardini,Marinus A. Blankenstein,Olivier Bousiges,Michael C. Camuso,Maria Berrocal Carrillo,Tiziana Casoli,Sebastiano Cavallaro,Odete A. da Cruz e Silva,Isabelle Cuvelier,Odile Delaroche,Roy B. Dyer,Sebastiaan Engelborghs,Anne Fogli,Orestes Vicente Forlenza,Nick C. Fox,Giovanni B. Frisoni,Daniela Galimberti,Elisabetta Galloni,Silvana Gritti,Karen H. Gylys,Harald Hampel,Sabine Haustein,Theresa Heath,Michael T. Heneka,Sanna-Kaisa Herukka,David M. Holtzman,Christian Humpel,Takeshi Iwatsubo,Claude Jardel,Mathias Jucker,Elisabeth Kapaki,Daniel Kidd,Péter Klivényi,Ryozo Kuwano,Foudil Lamari,Jean-Louis Laplanche,Jordan Laser,Sylvian Lehmann,Qiao-Xin Li,Walter Maetzler,Catherine Malaplate-Armand,Ralph Martin,Robert Martone,Colin L. Masters,Marc Mercken,Jose Luis Molinuevo,T. J. Montine,William Nowatzke,Markus Otto,Xavier Parent,Lucilla Parnetti,Ronald C. Petersen,Koen Poesen,Isabelle Quadrio,Muriel Quillard,Vara Luis Rello,Zdenek Rohan,Christin Sisowath,Anders Skinningsrud,Holly Soares,Hilkka Soininen,Knudsen Cindy Søndersø,Annette Spreer,Silvia Suardi,C.E. Teunissen,Robert M. Umek,Bianca Van Broeck,Rik Vandenberghe,László Vécsei,M.M. Verbeek,Igor Vostiar,Manfred Windisch +118 more
TL;DR: The cerebrospinal fluid biomarkers amyloid beta 1–42, total tau, and phosphorylated tau are used increasingly for Alzheimer's disease research and patient management, but there are large variations in biomarker measurements among and within laboratories.
Journal ArticleDOI
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
Stephanie J.B. Vos,Frans R.J. Verhey,Lutz Frölich,Johannes Kornhuber,Jens Wiltfang,Wolfgang Maier,Oliver Peters,Eckart Rüther,Flavio Nobili,Silvia Morbelli,Giovanni B. Frisoni,Alexander Drzezga,Mira Didic,Bart N.M. van Berckel,Andrew Simmons,Hilkka Soininen,Iwona Kłoszewska,Patrizia Mecocci,Magda Tsolaki,Bruno Vellas,Simon Lovestone,Cristina Muscio,Sanna-Kaisa Herukka,Eric Salmon,Christine Bastin,Anders Wallin,Arto Nordlund,Alexandre de Mendonça,Dina Silva,Isabel Santana,Raquel Lemos,Sebastiaan Engelborghs,Stefan Van der Mussele,Yvonne Freund-Levi,Åsa K. Wallin,Harald Hampel,Wiesje M. van der Flier,Philip Scheltens,Pieter Jelle Visser,Pieter Jelle Visser +39 more
TL;DR: The use of the proposed research criteria to identify Alzheimer's disease at the mild cognitive impairment stage and the use of both amyloid and neuronal injury markers as proposed by the National Institute of Ageing-Alzheimer Association criteria offers the most accurate prognosis are supported.